Media headlines about aTyr Pharma (NASDAQ:LIFE) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. aTyr Pharma earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.1449280727035 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of aTyr Pharma (LIFE) traded down 2.04% during mid-day trading on Tuesday, hitting $4.80. 25,859 shares of the stock traded hands. The stock’s market cap is $114.43 million. The firm’s 50 day moving average price is $4.74 and its 200-day moving average price is $4.74. aTyr Pharma has a 12-month low of $2.10 and a 12-month high of $6.50.

aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.06. Analysts predict that aTyr Pharma will post ($2.18) earnings per share for the current year.

LIFE has been the topic of several research reports. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research report on Wednesday, July 12th. ValuEngine raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. Finally, Piper Jaffray Companies initiated coverage on shares of aTyr Pharma in a research report on Thursday, September 7th. They set an “overweight” rating and a $7.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. aTyr Pharma presently has a consensus rating of “Hold” and a consensus target price of $4.62.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at

In related news, Director Paul Schimmel bought 94,336 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was purchased at an average price of $2.65 per share, for a total transaction of $249,990.40. Following the transaction, the director now directly owns 40,440 shares of the company’s stock, valued at approximately $107,166. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John Mendlein bought 37,736 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was bought at an average price of $2.65 per share, with a total value of $100,000.40. The disclosure for this purchase can be found here. 33.30% of the stock is owned by company insiders.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Insider Buying and Selling by Quarter for aTyr Pharma (NASDAQ:LIFE)

Receive News & Stock Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related stocks with our FREE daily email newsletter.